01.002 RWE TNT May 2022 B 17-05-2022

Calibrating real-world evidence studies against randomised trials

  • Real-world evidence (RWE) on the effectiveness of treatments in Crohn’s disease (CD) derived from clinical practice data will help fill many evidence gaps left by randomized controlled trials (RCTs)
  • Using claims data (2004–2019) from commercially insured patients in the United States (IBM MarketScan and Optum) and France (Système National des Données de Santé (National Healthcare Data System) (SNDS)), a cohort study of patients with CD who initiated combination therapy were compared with patients who initiated infliximab alone
  • These robust findings highlight opportunities in RWE analysis for studying treatment effectiveness in patients with CD in clinical practice
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at